Lv11
100 积分 2024-05-28 加入
reciprocal assistance
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
3小时前
已完结
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
2个月前
已完结
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
3个月前
已完结
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
4个月前
已完结
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
4个月前
已完结
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
4个月前
已完结
Current and Future Treatment Options in the Management of Stage III NSCLC
4个月前
已完结
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
5个月前
已完结
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
5个月前
已完结
Efficacy and safety of adjuvant EGFR TKI alone and in combination with chemotherapy for resected EGFR mutation-positive non-small cell lung cancer: A Bayesian network meta-analysis
6个月前
已完结
皖公网安备34019202002308
